

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Fatent and Trademark office

APPUICATION NO	FILING DATE	FIRST NAMED INVENTOR	ALTORNEY DOCKET NO	. 19 % 3 p% 53 1.1% 5, 1.
09 883,093	06 14 2001	Catherine Guenther	R-126	70126
-,	, rr vr 2 2. K r 2			
DELTAGEN, INC.			EXAMINER	
1003 Hamilton Menlo Park, Ca			WILSON, M	ICHAFL C
			ARTUNIT	PAPER NI MBE R
			.635	
			DATE MAILED 10/02/2002	1

Please find below and or attached an Office communication concerning this application or proceeding.



UNITED STAT DEPARTMENT OF COMMERCE Patent and Trauemark Office
ADDRESS:
ASSISTANT COMMISSIONER FOR PATENTS

APPLICATION NO.

FILING DATE

FIRST NAMED INVENTOR

ATTY. DOCKET NO.

EXAMINER

ART UNIT

PAPER NUMBER

DATE MAILED:

Washington, D.C. 20231

Please find below and/or attached an Office communication concerning the above identified application.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. **The sequences in Fig. 2A do not have a SEQ ID NO**. Applicants must file a "Sequence Listing" accompanied by directions to enter the listing into the specification as an amendment. Applicant also must provide statements regarding sameness and new matter with regards to the CRF and the "Sequence Listing."

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply. Failure to fully comply with the sequence rules in response to the instant office action will be considered non-responsive.

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of formal matters can be directed to the patent analyst, Dianiece Jacobs, who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-3388.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 308-4242.

Michael C. Wilson

Mil

MITTER TO MITTER

PTO-90C (Rev. 10.98)

Original for file, copy for mailing

Application No.: 09/883093

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7	Other: The sequence in Fig. 2A does not have a SEQ ID NO.
lf r	e	cessary, applicant Must Provide:
X	Α	substitute computer readable form (CRF) copy of the "Sequence Listing".
x		substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the pecification.
X	а	statement that the content of the paper and computer readable copies are the same and, where pplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
Fo	r q	uestions regarding compliance to these requirements, please contact:
Fo	r C	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE